Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia

Blood

Volumn 102, Issue 3, 2003, Pages 810-813

  Nieva, Jorge ^b   Bethel, Kelly ^b   Saven, Alan ^a  

^a SCRIPPS CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; ANTIPYRETIC ANALGESIC AGENT; CLADRIBINE; CORTICOSTEROID; DIPHENHYDRAMINE; PARACETAMOL; PENTOSTATIN; RITUXIMAB;

ABDOMINAL ABSCESS; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HAIRY CELL LEUKEMIA; HUMAN; LEUKEMIA REMISSION; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RELAPSE; SPLENECTOMY; TREATMENT FAILURE;

EID: 0042243678     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-01-0014     Document Type: Article

References (23)

1. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13:609-630.
2. Yam LT, Li CY, Lam KW. Tartrate-resistant acid phosphatase isoenzyme in the reticulum cells of leukemic reticuloendotheliosis. N Engl J Med. 1971;284:357-360.
3. Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med. 1990;322:1117-1121.
4. Goodman GG, Burian C, Saven A. An update: extended follow-up of patients with hairy cell leukemia following treatment with cladribine [abstract]. J Clin Oncol. 2001;20:305.
5. Kreitman RJ, Wilson WH, Bergeron K, et al. Efficacy of the anti-cd22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med. 2001;345:241-247.
6. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood. 1994;83:3672-3681.
7. Hagberg G. Chimeric monoclonal anti-CD20 antibody (rituximab) - an effective treatment for a patient with relapsing hairy cell leukaemia. Med Oncol. 1999;16:221-222.
8. Zinzani PL, Ascani S, Piccaluga PP, Bendandi M, Pileri S, Tura S. Efficacy of rituximab in hairy cell leukemia treatment. J Clin Oncol. 2000;18:3875-3877.
9. Hoffman M. Bone marrow remission of hairy cell leukaemia induced by rituximab in a patient refractory to cladribine. Br J Haematol. 2000;109:900-901.
10. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy of relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
11. Oken MM, Creech LH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
12. Hagberg H, Lundholm L. Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br J Haematol. 2001;115:609-611.
13. Lauria F, Lenoci M, Annino L, et al. Efficacy of anti-CD-20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica. 2001;86:1046-1050.
14. Thomas DA, O'Brien J, Cortes FJ, et al. A pilot study of rituximab in refractory or relapsed hairy cell leukemia [abstract]. J Clin Oncol. 1999;94(suppl 1):3116.
15. Demeter J, Paloczi K, Lehoczky D, Benczur M. Hairy cell leukaemia: observations on natural killer activity in different clinical stages of disease. Br J Haematol. 1989;71:239-244.
16. Seymour J, Kurzrock R, Freireich EJ, et al. 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood. 1994;83:2906-2911.
17. Saven A, Piro L. 2-Chlorodeoxyadenosine: a newer purine analogue active in the treatment of indolent lymphoid malignancies. Ann Intern Med. 1994;120:784-791.
18. Beutler E. Cladribine (2-chlorodeoxyadenosine). Lancet. 1992;340:952-956.
19. Jansen J, Hermans J. Splenectomy in hairy cell leukemia: a retrospective multicenter analysis. Cancer. 1981;47:2066-2076.
20. Grever M, Kopecky K, Foucar MK, Head D, et al. Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol. 1995;13:974-982.
21. Cassileth PA, Cheuvant B, Spiers AS, et al. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol. 1991;9:243-246.
22. Saven A, Emanuele S, Kosty M, Koziol J, Ellision D, Piro L. 2-Chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin lymphoma. Blood. 1995;86:1710-1716.
23. Canfield VA, Vose J, Guiney P, Bennett B, Nicohol C. 2-Chlorodeoxyadenosine as initial therapy for advanced low grade lymphoma. Leuk Lymphoma. 1997;24:335-339.